NEUMORA THERAPEUTICS INC (NMRA)

Company Profile

Neumora Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Watertown, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2023-09-15. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist in Phase 3 development as a potential monotherapy treatment for major depressive disorder (MDD). Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric disorders.

Company Info

NEUMORA THERAPEUTICS INC

490 Arsenal Way,, Suite 200

Watertown MASSACHUSETTS

P: 18577600900

Employees: 88

Website: https://neumoratx.com/